Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a major health and economic burden worldwide. Several mechanisms are involved in the pathoph...
Guardado en:
Autores principales: | Domingo Pascual-Figal, Antoni Bayés-Genis, Paola Beltrán-Troncoso, Pedro Caravaca-Pérez, Alicia Conde-Martel, Maria G. Crespo-Leiro, Juan F. Delgado, Javier Díez, Francesc Formiga, Nicolás Manito |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/367a0118f2f647ed9ac35f91293314da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert JJ, et al.
Publicado: (2020) -
Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
por: M. O.E. Irhuma, et al.
Publicado: (2016) -
Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy
por: Mohammad Abumayyaleh, et al.
Publicado: (2021) -
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
por: Elodie Charuel, et al.
Publicado: (2021) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
por: Karla L. Loss, et al.
Publicado: (2021)